Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen beiGene / BeOne Oncology Collaboration — R&D Cost Recovery ($M) ($M)
Form 10-Q / 10-K Collaborations Note (XBRL)
Latest, FY2025
181
Period ended Dec 31, 2025
Change on a year earlier
+48.4%
122 in FY2024
History
6 years
Since FY2020
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | BeiGene / BeOne Oncology Collaboration — R&D Cost Recovery ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 181 | +48.4% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 122 | +11.9% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 109 | -45.2% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 199 | -9.5% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 220 | -2.2% | Form 10-K (filed 2024-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 225 | – | Form 10-K (filed 2023-02-09) ↗ |
Breakdown
What makes up beigene / beone oncology collaboration — r&d cost recovery ($m)
Cite this data
StockData. (2026). Amgen BeiGene / BeOne Oncology Collaboration — R&D Cost Recovery ($M) ($M), annual FY2020–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/collab_beigene_rd
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.